Inventor · disambiguated record
Wayne A. Marasco
Also filed as: MARASCO WAYNE · MARASCO WAYNE A
55 granted patents·40 pending applications·917 citations·filing 1993–2025
98Inventor score
Top patents by PatentIndex Score
95 records- 0197US6329173B1Method of intracellular binding target moleculesDANA FARBER CANCER INST INC·Filed 2000·Granted Dec 11, 2001·81 cites·22 claims
- 0296US5965371AMethod of intracellular binding of target moleculesDANA FARBER CANCER INST INC·Filed 1995·Granted Oct 12, 1999·117 cites·101 claims
- 0395US5851829AMethod of intracellular binding of target moleculesDANA FARBER CANCER INST INC·Filed 1993·Granted Dec 22, 1998·152 cites·62 claims
- 0491US6830892B2Lentiviral vector system for high quantity screeningDANA FARBER CANCER INST INC·Filed 2001·Granted Dec 14, 2004·49 cites·16 claims
- 0590US9676867B2Chimeric T cell receptor comprising carbonic anhydrase IX (G250) antibodyDANA FARBER CANCER INST INC·Filed 2013·Granted Jun 13, 2017·13 cites·2 claims
- 0689US11174323B2Method of treating renal cancer using carbonic anhydrase IX (G250) antibodiesDANA FARBER CANCER INST INC·Filed 2019·Granted Nov 16, 2021·3 cites·20 claims
- 0789US8466263B2Carbonic anhydrase IX (G250) anitbodiesMARASCO WAYNE A·Filed 2006·Granted Jun 18, 2013·14 cites·17 claims
- 0889US7750123B2Antibodies against SARS-CoV and methods of use thereofDANA FARBER CANCER INST INC·Filed 2004·Granted Jul 6, 2010·20 cites·4 claims
- 0989US6143520AExpression vectors and methods of useDANA FARBER CANCER INST INC·Filed 1998·Granted Nov 7, 2000·124 cites·9 claims
- 1089US6004940AIntracellular targeting of endogenous proteinsDANA FARBER CANCER INST INC·Filed 1994·Granted Dec 21, 1999·114 cites·32 claims
- 1188US12024567B2Method of treating a tumor expressing carbonic anhydrase IX (G250) by administering a G250-specific chimeric antigen receptorDANA FARBER CANCER INST INC·Filed 2020·Granted Jul 2, 2024·1 cites·14 claims
- 1288US8329178B2Antibodies against CXCR4 and methods of use thereofMARASCO WAYNE A·Filed 2006·Granted Dec 11, 2012·14 cites·8 claims
- 1388US6479284B1Humanized antibody and uses thereofDANA FARBER CANCER INST INC·Filed 2000·Granted Nov 12, 2002·74 cites·32 claims
- 1487US10870705B2Chimeric antigen receptors specific for carbonic acid anhydrase IXDANA FARBER CANCER INST INC·Filed 2015·Granted Dec 22, 2020·2 cites·8 claims
- 1587US9828434B2Human monoclonal anti-PD-L1 antibodies and methods of useDANA FARBER CANCER INST INC·Filed 2013·Granted Nov 28, 2017·8 cites·11 claims
- 1687US9527924B2Humanized monoclonal antibodies and methods of useMARASCO WAYNE A·Filed 2011·Granted Dec 27, 2016·8 cites·4 claims
- 1786US10675349B2Humanized CC chemokine receptor 4 (CCR4) antibodies and methods of use thereofDANA FARBER CANCER INST INC·Filed 2015·Granted Jun 9, 2020·3 cites·25 claims
- 1884US12337034B2Humanized CC chemokine receptor 4 (CCR4) antibodies and methods of use thereofDANA FARBER CANCER INST INC·Filed 2023·Granted Jun 24, 2025·0 cites·28 claims
- 1984US9951122B2Antibodies against influenza virus and methods of use thereofDANA FARBER CANCER INST INC·Filed 2013·Granted Apr 24, 2018·4 cites·9 claims
- 2084US6072036AMethod of intracellular binding of target moleculesDANA FARBER CANCER INST INC·Filed 1999·Granted Jun 6, 2000·30 cites·5 claims
- 2184US2025011462A1Method of treating a tumor expressing carbonic anhydrase ix (g250) by administering a g250-specific chimeric antigen receptorDANA FARBER CANCER INST INC·Filed 2024·Application pending·0 cites
- 2283US2025243259A1Chimeric antigen receptors and methods of use thereofDANA FARBER CANCER INST INC·Filed 2024·Application pending·0 cites
- 2381US10400032B2Flavivirus neutralizing antibodies and methods of use thereofDANA FARBER CANCER INST INC·Filed 2017·Granted Sep 3, 2019·2 cites·3 claims
- 2481US7262049B2Pseudotyped lentiviral vectors and uses thereofDANA FARBER CANCER INST INC·Filed 2001·Granted Aug 28, 2007·10 cites·12 claims
- 2581US2025339521A1Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereofDANA FARBER CANCER INST INC·Filed 2025·Application pending·0 cites
- 2680US11046777B2Glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies and methods of use thereofDANA FARBER CANCER INST INC·Filed 2017·Granted Jun 29, 2021·1 cites·27 claims
- 2780US10604581B2Human monoclonal anti-PD-L1 antibodies and methods of useDANA FARBER CANCER INST INC·Filed 2017·Granted Mar 31, 2020·1 cites·15 claims
- 2880US10131704B2Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereofDANA FARBER CANCER INST INC·Filed 2015·Granted Nov 20, 2018·3 cites·19 claims
- 2980US9822166B2Flavivirus neutralizing antibodies and methods of use thereofDANA FARBER CANCER INST INC·Filed 2014·Granted Nov 21, 2017·3 cites·24 claims
- 3080US9441045B2Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of useDANA FARBER CANCER INST INC·Filed 2013·Granted Sep 13, 2016·2 cites·6 claims
- 3179US11104722B2Immunogenetic restriction on elicitation of antibodiesDANA FARBER CANCER INST INC·Filed 2019·Granted Aug 31, 2021·1 cites·1 claims
- 3278US9416169B2Humanized monoclonal antibodies and methods of useDANA FARBER CANCER INST INC·Filed 2015·Granted Aug 16, 2016·2 cites·18 claims
- 3376US5852186AReactive neutralizing human anti-GP120 recombinant antibody, DNA coding the same and use thereofDANA FARBER CANCER INST INC·Filed 1995·Granted Dec 22, 1998·36 cites·6 claims
- 3475US10450383B2Carbonic anhydrase IX (G250) antibodies and methods of use thereofDANA FARBER CANCER INST INC·Filed 2017·Granted Oct 22, 2019·1 cites·19 claims
- 3574US11135282B2Humanized influenza monoclonal antibodies and methods of use thereofDANA FARBER CANCER INST INC·Filed 2016·Granted Oct 5, 2021·1 cites·10 claims
- 3674US8962806B2Humanized monoclonal antibodies and methods of useMARASCO WAYNE·Filed 2008·Granted Feb 24, 2015·3 cites·13 claims
- 3774US7781568B2Anti-mullerian inhibiting substance type II receptor (MISIIR) immunoconjugates to detect and treat cancerFOX CHASE CANCER CT·Filed 2006·Granted Aug 24, 2010·2 cites·17 claims
- 3874US2024336694A1Compositions and methods for augmenting antibody mediated receptor signalingDANA FARBER CANCER INST INC·Filed 2023·Application pending·0 cites
- 3973US10556956B2Pharmaceutical compositions comprising humanized anti-CCR4 IgG4 antibodyDANA FARBER CANCER INST INC·Filed 2016·Granted Feb 11, 2020·1 cites·4 claims
- 4073US10179822B2Humanized monoclonal antibodies and methods of useDANA FARBER CANCER INST INC·Filed 2016·Granted Jan 15, 2019·1 cites·24 claims
- 4173US7078031B2Pseudotyped lentiviral vectors and uses thereofDANA FARBER CANCER INST INC·Filed 2004·Granted Jul 18, 2006·3 cites·3 claims
- 4272US8198411B2Anti-mullerian inhibiting substance type II receptor (MISIIR) immunoconjugates to detect and treat cancerADAMS GREGORY P·Filed 2010·Granted Jun 12, 2012·2 cites·10 claims
- 4371US12076390B2Humanized influenza monoclonal antibodies and methods of use thereofDANA FARBER CANCER INST INC·Filed 2021·Granted Sep 3, 2024·0 cites·11 claims
- 4471US10899825B2Flavivirus neutralizing antibodies and methods of use thereofDANA FARBER CANCER INST INC·Filed 2019·Granted Jan 26, 2021·0 cites·34 claims
- 4570US12195514B2Chimeric antigen receptors and methods of use thereofDANA FARBER CANCER INST INC·Filed 2020·Granted Jan 14, 2025·0 cites·12 claims
- 4670US11723973B2Humanized CC chemokine receptor 4 (CCR4) antibodies and methods of use thereofDANA FARBER CANCER INST INC·Filed 2020·Granted Aug 15, 2023·0 cites·32 claims
- 4769US11505597B2Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereofDANA FARBER CANCER INST INC·Filed 2020·Granted Nov 22, 2022·0 cites·33 claims
- 4868US2022135655A1Immunogenetic restriction on elicitation of antibodiesDANA FARBER CANCER INST INC·Filed 2021·Application pending·0 cites
- 4968US2025066481A1Fc variant compositions and methods of use thereofDANA FARBER CANCER INST INC·Filed 2024·Application pending·0 cites
- 5064US11261256B2Methods for depleting or inhibiting the migration of regulatory T-cells in early or late stages of cancerDANA FARBER CANCER INST INC·Filed 2020·Granted Mar 1, 2022·0 cites·18 claims
Showing the top 50 of 95 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Wayne A. Marasco files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →